In the Chinese program which is a 26-week, multicenter, phase III study to evaluate the efficacy and safety of ADA in Chinese CD population, patients with moderately to severely active CD who were receiving ADA achieved clinical remission in significantly greater proportions than those patients receiving placebo, and all enrolled patients were anti-ADA antibody-negative throughout the study (Chen et al., 2020). The gene discussed is ADA; the disease is Cowden disease.